Pan-cancer analysis reveals CCL5/CSF2 as potential predictive biomarkers for immune checkpoint inhibitors
Open Access
- 10 September 2024
- journal article
- research article
- Published by Springer Nature in Cancer Cell International
- Vol. 24 (1) , 1-13
Abstract
Currently, there are no optimal biomarkers available for distinguishing patients who will respond to immune checkpoint inhibitors (ICIs) therapies. Consequently, the exploration of novel biomarkers that can predict responsiveness to ICIs is crucial in the field of immunotherapy. We estimated the proportions of 22 immune cell components in 10 cancer types (6,128 tumors) using the CIBERSORT algorithm, and further classified patients based on their tumor immune cell proportions in a pan-cancer setting using k-means clustering. Differentially expressed immune genes between the patient subgroups were identified, and potential predictive biomarkers for ICIs were explored. Finally, the predictive value of the identified biomarkers was verified in patients with urothelial carcinoma (UC) and esophageal squamous cell carcinoma (ESCC) who received ICIs. Our study identified two subgroups of patients with distinct immune infiltrating phenotypes and differing clinical outcomes. The patient subgroup with improved outcomes displayed tumors enriched with genes related to immune response regulation and pathway activation. Furthermore, CCL5 and CSF2 were identified as immune-related hub-genes and were found to be prognostic in a pan-cancer setting. Importantly, UC and ESCC patients with high expression of CCL5 and low expression of CSF2 responded better to ICIs. We demonstrated CCL5 and CSF2 as potential novel biomarkers for predicting the response to ICIs in patients with UC and ESCC. The predictive value of these biomarkers in other cancer types warrants further evaluation in future studies.Keywords
Funding Information
- Natural Science Foundation Committee, China (82003221, 82173011, 81901801)
- Department of education of Guangdong Province, China (2019KQNCX032)
- Science and technology projects of Shantou, China (200601155261081)
- Cancer Hospital of Shantou University Medical College, China (2020A001)
- Natural Science Foundation of Guangdong Province, China (2019A1515010239, 2021A1515011180)
- Shantou Central Hospital Research Incubation Program, China (201905)
This publication has 44 references indexed in Scilit:
- Robust enumeration of cell subsets from tissue expression profilesNature Methods, 2015
- Nivolumab in Previously Untreated Melanoma withoutBRAFMutationNew England Journal of Medicine, 2015
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic ActivityCell, 2015
- The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory CheckpointsCancer Discovery, 2015
- Treg functional stability and its responsiveness to the microenvironmentImmunological Reviews, 2014
- Oncogenic Kras-Induced GM-CSF Production Promotes the Development of Pancreatic NeoplasiaCancer Cell, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Monocyte and macrophage heterogeneityNature Reviews Immunology, 2005
- X-TileClinical Cancer Research, 2004